Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $476.95, moving +1.45% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.78% ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo & Co. (WFC), Abbott ...

This was the stock's second consecutive day of gains.

The stock's rise snapped a three-day losing streak.

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

NRI PULSE STAFF REPORT The 2025 edition of TIME100 Most Influential Companies honors leaders and innovators who are ...

Key Points Alibaba is a Chinese AI stock that's dirt cheap. Meta Platforms is making a huge bet on AI that should pay off ...

NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...